Panobinostat (LBH589)

目录号:S1030 别名: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Phase 3。

规格 价格 库存 购买数量  
RMB 731.86 现货
RMB 2189.52 现货
RMB 5485.18 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献122篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Panobinostat (LBH589)是一种新型的,广谱HDAC抑制剂,无细胞试验中IC50为5 nM。Phase 3。
靶点
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
体外研究

LBH589诱导MOLT-4和Reh细胞凋亡,这种作用具有时间和剂量依赖性。而且,LBH589作用于MOLT-4细胞比作用于Reh细胞更有效。LBH589明显阻止MOLT-4 和Reh细胞的生长,处理48小时,具有剂量依赖性。与对照组细胞相比,用LBH589处理的细胞,在细胞周期的G2/M期的细胞数量增多2到3倍。LBH589与组蛋白H3K9和H4K8的乙酰化作用相关,LBH589也降低c-Myc的表达水平,具有剂量依赖性。LBH589也增强p21的表达水平。最低剂量的LBH589(10 nM)处理Reh细胞,最初增强c-Myc的表达水平,之后一直降低c-Myc的表达水平。此外,LBH589促进mRNA水平的促凋亡和DNA修复基因的大量增多。在GADD45G启动子作用下,LBH589诱导乙酰化的组蛋白H3 和H4水平的增多。[1]此外, LBH589抑制非小细胞肺癌细胞系生长,如人类H1299,L55和A549,IC50分别为5,11和30 nM;间皮瘤细胞生长,如人类OK-6和 Ok-5,IC50分别为5和7 nM;及小细胞肺癌细胞系生长,如人类RG-1和LD-T,IC50分别为4和5 nM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NHHEO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUiwMVExKM7:TR?= MV[wMVQh\A>? NVXLdGdFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NG\tZVMzPjdyMke4OC=>
HepG2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v5VFAuOTBizszN NYXXWo5POC12IHS= NXGzPWpJcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXfkOI9TOjZ5MEK3PFQ>
HT29 NXrifnVkTnWwY4Tpc44hSXO|YYm= NUTUVGVVPTEEoH7N NHTBfnEzPC15MjDo MknobY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkA1QMLiaNMg NIHYZVkzPjdyMke4OC=>
HepG2 M4izO2Z2dmO2aX;uJGF{e2G7 MnTYOVDDqG6P MWeyOE04OiCq NE[xeVhqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|IHHmeIVzKDJ2wrDoxsA> MnLQNlY4ODJ5OES=
HCC827 M4nNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVW1M|cvPS9zMDDuUS=> M1XSdlczyqCq NWLOeGZqTE2VTx?= MYXlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NIHKU3UzPjZ5NUS4OC=>
A549  NUPsXYZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\ZNVAwOTVxMkCgcm0> MoTzO|LDqGh? MlzaSG1UVw>? NGPlfXNmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= Mn3qNlY3PzV2OES=
NCI-H460  M1ixWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3qwbFExNzJyL{OwJI5O NGDLXYw4OsLiaB?= MX;EUXNQ NUi1UWhO\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= NVT1XIZ6OjZ4N{W0PFQ>
J89GFP MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;KSG1UV8Li MX3FR|UxRTR7Lki1JOKyKDF{Lk[1JI5O NGK4d2czPjV4M{W2PC=>
THP89GFP M4fqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof2SG1UV8Li NEf0d25GSzVyPUG5MlM1KMLzIE[uOFMhdk1? MVyyOlU3OzV4OB?=
SK-NEP-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz0[3gxNjBz4pETNVAvOCEQvF2= MlTLNlQhcA>? MnG0SG1UV8Li NXjENG5SUUN3ME23Ok4{PCCwTR?= NYHVWVJ4OjZzN{[yNVk>
G401 NGDZW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MViwMlAy6oDVMUCuNEDPxE1? MX:yOEBp MYjEUXNQyqB? NHKycohKSzVyPUG0N{4xOiCwTR?= MljDNlYyPzZ{MUm=
SK-NEP-1 NGn2fXFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHzxfZc2OCCwTR?= MUOx5qCUPCCm NX7iO3JkTE2VT9Mg NIW0VoJz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? Mor4NlYyPzZ{MUm=
G401 M{H5U2NmdGxiVnnhZoltcXS7IFHzd4F6 MWi1NEBvVQ>? MmPKNgKBmzRiZB?= NVrnZnNVTE2VT9Mg Ml64doVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz NFTXSpozPjF5NkKxPS=>
SK-NEP-1 MX7BdI9xfG:|aYOgRZN{[Xl? M325fFUxNzFyMDDuUS=> MmD4NlQhcA>? MXrEUXNQyqB? MWLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWSyOlE4PjJzOR?=
G401 NYHMXW1HSXCxcITvd4l{KEG|c3H5 NYfqfXZtPTBxMUCwJI5O NUnCV5ZnOjRiaB?= M3fIPWROW00EoB?= NFfZXGNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Ml;WNlYyPzZ{MUm=
SK-NEP-1 NUTUZWZrTnWwY4Tpc44hSXO|YYm= MYK1NE8yODBibl2= NVzWR4M4OjRiaB?= NFzOcldFVVORwrC= M1LyO5Npd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? MkSzNlYyPzZ{MUm=
G401 MUHGeY5kfGmxbjDBd5NigQ>? NUfkUGs6PTBxMUCwJI5O NWTySYpiOjRiaB?= Mn\qSG1UV8Li M3zDWpNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? MV2yOlE4PjJzOR?=
SK-NEP-1 MUfGeY5kfGmxbjDBd5NigQ>? Moq3OVAwOTByIH7N NV3MepV7OjRiaB?= MmDQSG1UV8Li M{nCbIlv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh MYCyOlE4PjJzOR?=
G401 NX;HXYMzTnWwY4Tpc44hSXO|YYm= NHrXSJo2OC9zMECgcm0> Ml;2NlQhcA>? MXrEUXNQyqB? NXG1NY9ZcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? MUSyOlE4PjJzOR?=
RPMI 8226 MWLD[YxtKFO3co\peoFtKEG|c3H5 NITNUJczNzRxNjDuUS=> NHTpTpk1QOLCiXi= NHGzfpFqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq MkXpNlYxODB{OUK=
OPM2 NFq4emhE\WyuIGP1dpZqfmGuIFHzd4F6 NF74NGozNzRxNjDuUS=> NV;DWG9XPDkkgJno M1izWIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? MYOyOlAxODJ7Mh?=
U266 NGTJTHNE\WyuIGP1dpZqfmGuIFHzd4F6 NGDKPW0zNzRxNjDuUS=> MWe0PQKBkWh? M3zL[olv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? MXyyOlAxODJ7Mh?=
H929 MljDR4VtdCCVdYL2bZZidCCDc4PhfS=> NID1UmgzNzRxNjDuUS=> NXHjcllWPDkkgJno NW\zfJVscW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= MVmyOlAxODJ7Mh?=
RPMI 8226  NHPCXmpCeG:ydH;zbZMhSXO|YYm= M2TLd|TjiImwTR?= NYjmcot[OjRxNEigbC=> NVrEZYR4cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NHjKWVczPjByMEK5Ni=>
HCC827 NGLCOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHhengyOCCwTR?= NYnoT2FiPDhiaB?= NHy1XFRFVVOR NF20ZlRmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= M{DSZVI2QTR2NkG3
NCI-H23 NVX4dopCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS3V4wyOCCwTR?= M2DQSFQ5KGh? NIq1UIZFVVOR M3n1SYVvcGGwY3XzJINqe3CuYYTpckB{\W6|aYTpeol1gcLi NYfNU4xqOjV7NES2NVc>
AML3 NGnwNYlHfW6ldHnvckBCe3OjeR?= NIjnSYcxNTFizszN NWXRcm1zOjUEoHi= M3;ybYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4PaelI2PjF{OUSx
ML-1 NXLxWVJQTnWwY4Tpc44hSXO|YYm= MVOwMVEh|ryP NEHaZ4MzPMLiaB?= M{jJXYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVWzUnY6OjV4MUK5OFE>
RPMI-8226vr10  MVnGeY5kfGmxbjDBd5NigQ>? MmrVNE0yKM7:TR?= M{DBbVI1yqCq NFrVNGVqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHTKNFMzPTZzMkm0NS=>
ML-1 MYfGeY5kfGmxbjDBd5NigQ>? NGjZR|QyKM7:TR?= M4fiSlI1yqCq M4n4Tolv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhPC2ob3zk NHHoXIkzPTZzMkm0NS=>
RPMI-8226vr10  NYXWd|FYTnWwY4Tpc44hSXO|YYm= NEK0R4QyKM7:TR?= NGX3PI4zPMLiaB?= M2K5Xolv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhOi53LX\vcIQ> MXKyOVYyOjl2MR?=
SK-N-BE (2) MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLHflUxOjUkgJno MnHLTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P Mk\YNlU{ODh7MU[=
SK-N-BE (2), PAN  MK MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzPWJIzPOLCiXi= NX\6WIpMUUN3ME2xNFQvOOLCidMx5qCKPy56IH7N NY\ZNGlCOjV|MEi5NVY>
SK-N-BE (2), MK  PAN MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTESGMzPOLCiXi= M4XTO2lEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2= Mnj0NlU{ODh7MU[=
SK-N-AS M{DIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOyOQKBkWh? M{HJfmlEPTB;M{euNgKBkcLz4pEJNk41KG6P NV64WZBmOjV|MEi5NVY>
SK-N-DZ M1PoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrJcZMzPOLCiXi= MnzZTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1? MoXpNlU{ODh7MU[=
Caki-1 MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPzdHV5OTBxMkWvOVAhdk1? NInKdJI1QCCq NED4e3pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MmHFNlUzPzlzOUG=
ACHN MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXixNE8zPS93MDDuUS=> M3HGO|Q5KGh? MnvBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ NUHzemdwOjV{N{mxPVE>
769-P M4TJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWKxNE8zPS93MDDuUS=> MVO0PEBp NHz1bIhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MVGyOVI4QTF7MR?=
786-O  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrTNVAwOjVxNUCgcm0> NIXze2I1QCCq NU\rWnBGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny MVyyOVI4QTF7MR?=
Caki-1 M3K0bGFxd3C2b4Ppd{BCe3OjeR?= M2DXfVUxKG6P MYm0PEBp NGXk[nNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= MXWyOVI4QTF7MR?=
ACHN MkHXRZBweHSxc3nzJGF{e2G7 Mo\YOVAhdk1? MYW0PEBp NXXRT5RPcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= MWeyOVI4QTF7MR?=
769-P NF7nXHlCeG:ydH;zbZMhSXO|YYm= MlvuOVAhdk1? MVi0PEBp NEDpeJZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= MVyyOVI4QTF7MR?=
786-O  MmfqRZBweHSxc3nzJGF{e2G7 Mnq0OVAhdk1? NH3HeXM1QCCq MXjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? Mk\KNlUzPzlzOUG=
Caki-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vnWVI2NzVyIH7N MXW0PEBp Mlq0SG1UVw>? NYrMcmVGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> MV[yOVE4PjN3NB?=
ACHN M1[1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHuc|JEOjVxNUCgcm0> NGfnXpI1QCCq M4C3OGROW09? MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk M2LjbVI2OTd4M{W0
769-P Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37IXVI2NzVyIH7N NEnK[FE1QCCq MnXjSG1UVw>? NXOxfo45cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=> NH\hb4QzPTF5NkO1OC=>
Caki-1 M3HlfGNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? MV[1NEBvVQ>? NXLhfFNuPy1zNDDk MVjEUXNQ M1ThV5N2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh NX;YS3RkOjVzN{[zOVQ>
ACHN M3u4cGNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? NXzzWmtnPTBibl2= NHzFfWM4NTF2IHS= MlO0SG1UVw>? MmS0d5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> NFnLSYwzPTF5NkO1OC=>
769-P M{O3SWNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? M1LGSVUxKG6P MkW2O{0yPCCm MVLEUXNQ NWHiO3dQe3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? NXvpNI9JOjVzN{[zOVQ>
Caki-1 M1mwXmFxd3C2b4Ppd{BCe3OjeR?= NHLB[pk2OCCwTR?= NF\KZ4Q1QCCq M2rRTmROW09? NFvzNnFqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHO4O|EzPTF5NkO1OC=>
ACHN NV3IcGN3SXCxcITvd4l{KEG|c3H5 NEnYeI02OCCwTR?= MXS0PEBp NXK1[|JjTE2VTx?= MXLpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NYXQelB[OjVzN{[zOVQ>
769-P MVHBdI9xfG:|aYOgRZN{[Xl? NXrZeGlbPTBibl2= MUC0PEBp NXvQemZrTE2VTx?= MXnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NUDVeG1xOjVzN{[zOVQ>
MDA-MB-231 MWjNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> NUK0fXF7OTEEoH7N NFrsNlg{yqCm NYHTRVhpTE2VTx?= MX7hcJRmenNiY3XscEBud3KyaH;sc4d6yqB? NVnhU|VROjR6MUC0PVc>
BT-549 MV7Nc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> MXWxNOKhdk1? M{Dhb|PDqGR? MXrEUXNQ MYXhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? M4m2RlI1QDFyNEm3
MCF-7  MoLjUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 MV:xNOKhdk1? Mnq4N:Kh\A>? M1rqXGROW09? MnHPZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NHjJ[5gzPDhzMES5Oy=>
MCF-7 MUnGeY5kfGmxbjDBd5NigQ>? MmX6OU02OCCwTR?= Ml[zNlQhcA>? NWPjRm9uTE2VTx?= NVO1SoNIemWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>? M4XJ[FI1OzZ4NEC3
CTS NWS5dlh4SXCxcITvd4l{KEG|c3H5 M4XYPFDjiJN2MDDuUeKh NIXUfmI1QCCq NXzLTZJmcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUjIWYpJOjR{NES0Nlk>
OCI-AML3  MmXyRZBweHSxc3nzJGF{e2G7 M1HmOVDjiJN2MDDuUeKh NWT0SYF7PDhiaB?= M37tUIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVHZUYs6OjR{NES0Nlk>
U937 NUXybFRESXCxcITvd4l{KEG|c3H5 Mo\nNQKBmzRyIH7NxsA> Mm[yOFghcA>? M4DUbIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFLWUFczPDJ2NESyPS=>
PC3 M{T4ZWFxd3C2b4Ppd{BCe3OjeR?= MXKwMVExOCCwTR?= M3Pm[FI1NzR6IHi= MVXpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{PzW|I1OTZ|MkOw
PC3-AR MVfBdI9xfG:|aYOgRZN{[Xl? MkfGNE0yODBibl2= NGfaeZUzPC92ODDo NULr[|dLcW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHTHe5EzPDF4M{KzNC=>
PC3 M2nhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfZTI1nOC1zMECgcm0> NH3Y[5gzPC92ODDo MWnpcoR2[2W|IHHjZ5VufWyjdHnvckBw\iC|dXLHNUBxd3C3bHH0bY9v Mki3NlQyPjN{M{C=
PC3-AR MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPxNHk5OC1zMECgcm0> M371RVI1NzR6IHi= MWnpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJJRp\SCJMl2gdIhie2V? NFTwV40zPDF4M{KzNC=>
PC3 NGDPS5pHfW6ldHnvckBCe3OjeR?= NXfiTmx2OC1zMECgcm0> M4O3d|I1KGh? NY[2XZM1e3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> MYqyOFE3OzJ|MB?=
PC3-AR Mk\xSpVv[3Srb36gRZN{[Xl? NH;GUZoxNTFyMDDuUS=> NG\LXmYzPCCq MkW1d5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= M{XSblI1OTZ|MkOw
OS-RC-2 MoXSR4VtdCCYaXHibYxqfHliQYPzZZk> Mny3NE0yODByIH7N NHrZXpUzPC92OD:3NkBp M4ntcGROW09? Mn7S[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXSyOFE1PDd|Nx?=
OS-RC-2 MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HudlUxKG6P NW\D[lVFPDhiaB?= NYC3XWZkTE2VTx?= NIHsXGtqdmS3Y3XzJGczN01iYYLy[ZN1 MkfONlQyPDR5M{e=
OS-RC-2 MUnBdI9xfG:|aYOgRZN{[Xl? MUm1NEBvVQ>? MnLiOFghcA>? NWnSfnlFTE2VTx?= MYjpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXmyOFE1PDd|Nx?=
SK-N-AS MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2w5qCUQDBibl2= MVW0PEBp M{HmbWlEPTB;MkeuOEBvVQ>? NHviZpczPDB7OEe5PS=>
SK-N-DZ MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXsNQKBmzhyIH7N M2Ozd|Q5KGh? M4nrWWlEPTB;MkGuPUBvVQ>? M{nSd|I1ODl6N{m5
SK-N-SH Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETpV2wx6oDVOECgcm0> M363bVQ5KGh? NGPzTpZKSzVyPUeyMlMhdk1? NXLHcHQ3OjRyOUi3PVk>
SK-N-BE NH[wUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWew5qCUQDBibl2= MWm0PEBp MWTJR|UxRTd3LkSgcm0> MYKyOFA6QDd7OR?=
SK-N-AS NUPwUm9ySXCxcITvd4l{KEG|c3H5 M4\rR|DjiJN6MDDuUS=> M{nMU|Q5KGh? MmjqdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NXrLT2hbOjRyOUi3PVk>
SK-N-DZ MXzBdI9xfG:|aYOgRZN{[Xl? MX2w5qCUQDBibl2= NUH4WnhPPDhiaB?= NVfvTmFOeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NHK0[5ozPDB7OEe5PS=>
SK-N-SH MnS0RZBweHSxc3nzJGF{e2G7 NG[5NoMx6oDVNECgcm0> NELmeFY1QCCq NILP[VBxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> NGnXfnIzPDB7OEe5PS=>
SK-N-BE M4DiWWFxd3C2b4Ppd{BCe3OjeR?= NFPrbYsx6oDVNECgcm0> MVW0PEBp M1;MW5BwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> M1\GeFI1ODl6N{m5
SK-N-AS MX;GeY5kfGmxbjDBd5NigQ>? NHL0N5Qx6oDVOECgcm0> MlyzOFghcA>? MlLxbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> M4LtfFI1ODl6N{m5
SK-N-DZ MYjGeY5kfGmxbjDBd5NigQ>? M{S5WlDjiJN6MDDuUS=> MlfTOFghcA>? NGfEdWRqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR NUTy[opROjRyOUi3PVk>
SK-N-SH M1vISGZ2dmO2aX;uJGF{e2G7 M1G1SVDjiJN2MDDuUS=> NXHMU5NRPDhiaB?= NWfh[o82cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? NFXiWI0zPDB7OEe5PS=>
SK-N-BE NWD6U5JMTnWwY4Tpc44hSXO|YYm= MonnNQKBmzRyIH7N NIDOTYk1QCCq M4DUcolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MofoNlQxQTh5OUm=
HCC-LM3 M17ubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVixMVExODBibl2= M1\TUFI1NzR6L{eyJIg> MkDnSG1UVw>? NUHpNpVycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYOxO|ZIOjRyOUO5OVY>
HepG2 NHS0O3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfiNU0yODByIH7N NELOOY8zPC92OD:3NkBp MUXEUXNQ MnXjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFfyOo4zPDB7M{m1Oi=>
SMMC-7721 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnKNU0yODByIH7N MVyyOE81QC95MjDo MmDRSG1UVw>? MnnTbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnPmNlQxQTN7NU[=
HCC-LM3 NVHFdpZoSXCxcITvd4l{KEG|c3H5 M3vOdFUxKG6P MlXiOFghcA>? MXzEUXNQ NUXmb5BMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? NWTEW|F6OjRyOUO5OVY>
HepG2 NVKyW4ZbSXCxcITvd4l{KEG|c3H5 M33j[|UxKG6P MV:0PEBp MUfEUXNQ MnTobY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> MVWyOFA6Ozl3Nh?=
SMMC-7721 NFTrO3RCeG:ydH;zbZMhSXO|YYm= MWq1NEBvVQ>? NUi4[YVYPDhiaB?= M4\Je2ROW09? M3PrS4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 M{P4bVI1ODl|OUW2
HCC-LM3 M1nu[WZ2dmO2aX;uJGF{e2G7 MXO1NE8yODBibl2= NWW4NJNiOjRiaB?= M2PHb2ROW09? MoS3[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= M2fQeVI1ODl|OUW2
HepG2 MnKxSpVv[3Srb36gRZN{[Xl? NWnXOFZ3PTBxMUCwJI5O NX3lW2dYOjRiaB?= MUPEUXNQ NYDjbFVZ\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> M3TINFI1ODl|OUW2
SMMC-7721 M4HYW2Z2dmO2aX;uJGF{e2G7 MmjaOVAwOTByIH7N MYmyOEBp NX\WWVMzTE2VTx?= NXruS41H\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> NXuxcFVbOjRyOUO5OVY>
HCC-LM3 MmnZSpVv[3Srb36gRZN{[Xl? M3fRTlUxNzFyMDDuUS=> NHPiUW4zPCCq M4DiTWROW09? M1O2fIRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? Ml7SNlQxQTN7NU[=
HepG2 NIXab3FHfW6ldHnvckBCe3OjeR?= Mn;IOVAwOTByIH7N MlflNlQhcA>? NVjiO|Z7TE2VTx?= NXfj[JBZ\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NW\0dXBCOjRyOUO5OVY>
SMMC-7721 M1jIUWZ2dmO2aX;uJGF{e2G7 MVG1NE8yODBibl2= NInE[2wzPCCq NVvTXIRHTE2VTx?= MUHkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v MkjrNlQxQTN7NU[=
FaDu MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v4NlExOOLChX7N MX[4M|ExNzF{IHi= NG\idHFlcXOybHH5[YQh[SC|aXfubYZq[2GwdDDhcoQheHKxbH;u[4VlKEd{L12gZZJz\XO2IHH0JFgh[W6mIEGy5qCGcCCyb4P0JJJmdGWjc3W= MWmyOFAzPjR6Mh?=
FaDu MWrGeY5kfGmxbjDBd5NigQ>? M3HBO|ExOOLChX7N MYWyM|QwQC9zMjDo M{PaOYlv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w MmrXNlQxOjZ2OEK=
PC-3  NI\yc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuwMVExKM7:TR?= NUXCW2JUOjRxNEivO|IhcA>? M2rBPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHrGOmkzOzl7MUKxOi=>
LNCaP NIP6fJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKwMVUh|ryP MlHkNlQwPDhxN{KgbC=> NF35bFhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Ml2xNlM6QTF{MU[=
RWPE-1  NXuyXVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\afFAuOjBizszN NEfOU40zPC92OD:3NkBp MmPsbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkDoNlM6QTF{MU[=
Capan-1 NXLmOlZuTnWwY4Tpc44hSXO|YYm= NULrSJJbOjVxNUCvNVAxKG6P NIHtcIg5NzJ2L{S4JIg> M3;TV2ROW09? M4DM[4Rwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= NUnldW1QOjN7MkK4PFY>
L3.6pl NGPW[lNHfW6ldHnvckBCe3OjeR?= NEHyeXIzPS93MD:xNFAhdk1? MXO4M|I1NzR6IHi= MYPEUXNQ M1zz[oRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= M2HVc|I{QTJ{OEi2
CFPAC-1  NYnDVIRmTnWwY4Tpc44hSXO|YYm= NU\JWVlrOjVxNUCvNVAxKG6P NG\SblM5NzJ2L{S4JIg> Mny3SG1UVw>? NYDMTWVP\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> NXnEPFlwOjN7MkK4PFY>
Capan-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOyOU82OC9zMECgcm0> NFfBZo81QCCq M2PhNGROW09? MU\y[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NH7nTpIzOzl{Mki4Oi=>
L3.6pl MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYiyOU82OC9zMECgcm0> NVfhVWh2PDhiaB?= M4nmdmROW09? M1HqepJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1;ORVI{QTJ{OEi2
CFPAC-1  MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTjWGwzPS93MD:xNFAhdk1? M{\EOlQ5KGh? MV3EUXNQ NGjHfFVz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NH;GUVAzOzl{Mki4Oi=>
Capan-1 NVf3S2tNSXCxcITvd4l{KEG|c3H5 M1nDSFI2NzVyL{GwNEBvVQ>? NX;RSppRPDhiaB?= NGOyR5BFVVOR NHfJXHdqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYLSUIROOjN7MkK4PFY>
L3.6pl NX[xOJdISXCxcITvd4l{KEG|c3H5 NXL1eY9yOjVxNUCvNVAxKG6P MmrOOFghcA>? NFfibGhFVVOR NYn2TI1FcW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYf4WlJIOjN7MkK4PFY>
CFPAC-1  MnnFRZBweHSxc3nzJGF{e2G7 M4HqZlI2NzVyL{GwNEBvVQ>? MlPYOFghcA>? NVrMV|NlTE2VTx?= NHzoflJqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2nFUVI{QTJ{OEi2
HN22 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\nTFlYOC1{MDDuUS=> M4rZZ|I1NzR6IHi= NFTxPIFFVVOR MVTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy M4TGR|I{QDd5MkO1
HSC4  NWHDTWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW2WFJLOC1{MDDuUS=> M3HUbFI1NzR6IHi= MnjjSG1UVw>? M1nzZ4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> MkDQNlM5Pzd{M{W=
HN22 MnzXRZBweHSxc3nzJGF{e2G7 NEfpRpgxNTJyIH7N M37BNFQ5KGh? Mo[3SG1UVw>? MlfXbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NFrmTXYzOzh5N{KzOS=>
HSC4  MW\BdI9xfG:|aYOgRZN{[Xl? NGTmbogxNTJyIH7N NVfXOnlRPDhiaB?= NIHo[5RFVVOR MV7pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MkX4NlM5Pzd{M{W=
HN22 M4X5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX2wMVIxKG6P MnXxOFghcA>? NXq3fHNPTE2VTx?= MX\pcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= M{LpTFI{QDd5MkO1
HSC4  MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjWfWgxNTJyIH7N MljDOFghcA>? NVSweFlOTE2VTx?= NYPtN|BMcW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh MormNlM5Pzd{M{W=
HN22 NUPBXnNlTnWwY4Tpc44hSXO|YYm= Mn[3NE0zOCCwTR?= M3P5e|Q5KGh? MoHKSG1UVw>? MojUd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg NXLaOpRzOjN6N{eyN|U>
HSC4  Mn\ESpVv[3Srb36gRZN{[Xl? NEfYRlkxNTJyIH7N MkjLOFghcA>? NVTuN4c3TE2VTx?= Mli2d5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg M2m4RlI{QDd5MkO1
Cal62 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HuPGlEPTB;M{OgxtEhPCCwTR?= MUeyN|gzPDB4NB?=
Hth7 NIfEcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjSVGU2UUN3ME2xOUDDuSB{IH7N NF36UW0zOzh{NEC2OC=>
Hth83 NXj2OndFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G3bWlEPTB;M{SgxtEhPSCwTR?= M2G1S|I{QDJ2ME[0
C643 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zVOGlEPTB;N{GgxtEhOTBibl2= NXuzeZZjOjN6MkSwOlQ>
SW1736 NYrNZ4JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzwXXBKSzVyPUO1JOKyKDhibl2= Mn7HNlM5OjRyNkS=
T241 Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{niNWlEPTB;NkWgxtEhPyCwTR?= NWnhbnR7OjN6MkSwOlQ>
T351 NWHBeWtLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP0TWM2OD13MDFCtUAyOCCwTR?= NF;EWHAzOzh{NEC2OC=>
BHP2-7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPZNmJbUUN3ME2zO{DDuSB4IH7N M2\ae|I{QDJ2ME[0
T238 NV:0XlRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHMTWM2OD1zLEWwNEDDuSB{MECgcm0> MnrtNlM5OjRyNkS=
HCT8 MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGxO|IhcA>? Mk\ySG1UVw>? M{XSXmlEPTB;MUKuPgKBkcLz4pEJNU46KG6P MWiyN|I6QTN6OB?=
H630 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XuZlczKGh? M3LEV2ROW09? MWjJR|UxRTF{LkVihKnDueLCiUOuNUBvVQ>? M336b|I{Ojl7M{i4
cH630 5-FU-res MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHaU3U4OiCq Mn\lSG1UVw>? M4rETWlEPTB;MUWuOgKBkcLz4pEJNU4zKG6P NF7uZ2ozOzJ7OUO4PC=>
HCT116 MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfkVoI4OiCq MlT0SG1UVw>? MoPJTWM2OD1zMD635qCKyrIkgJmyMlIhdk1? Mmn4NlMzQTl|OEi=
HCT116 p53−/− MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVm3NkBp Ml3QSG1UVw>? Moq1TWM2OD16LkdihKnDueLCiUGuO{BvVQ>? MnjoNlMzQTl|OEi=
dHCT116 p21−/− M1TMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[2O|IhcA>? NUS0NIxpTE2VTx?= NXnP[HV3UUN3ME21MlnjiIoEsfMAjVEvOyCwTR?= Ml\qNlMzQTl|OEi=
HT29 NFTheGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX4bVI4OiCq NFXBXG5FVVOR MlzhTWM2OD1zNj6z5qCKyrIkgJmyMlMhdk1? MUmyN|I6QTN6OB?=
LoVo NIjudIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUK3NkBp NXXsR2g3TE2VTx?= MV3JR|UxRTVwMfMAjeKy6oDLMD62JI5O NYnm[nRPOjN{OUmzPFg>
RKO M4XXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH2O|IhcA>? NFPn[FFFVVOR M4PF[2lEPTB;Nz655qCKyrIkgJmyMlIhdk1? NUX4R5BjOjN{OUmzPFg>
SW480 NEHWe3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkToO|IhcA>? M2fSXWROW09? NIeyfnFKSzVyPUG3MlXjiIoEsfMAjVAvQCCwTR?= NHjOUmgzOzJ7OUO4PC=>
eSW620 NGG5U5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[3NkBp NWHqZ2xmTE2VTx?= MVfJR|UxRTlwMfMAjeKy6oDLMj6xJI5O M4HhXlI{Ojl7M{i4

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
体内研究 LBH589作用于患肺癌和间皮瘤动物模型,明显降低肿瘤生长,与对照组相比平均降低62%。LBH589作用于免疫活性鼠和严重联合免疫缺陷鼠效果差不多,说明LBH589抑制肿瘤生长与免疫学无关。LBH589按20 mg/kg剂量腹腔注射,每周持续5天,导致在实验最后肿瘤生长平均下降70%。与相应的对照组肿瘤相比,LBH589作用于H526衍生的肿瘤下降53%,作用于BK-T衍生的肿瘤下降81%, 作用于RG-1衍生的肿瘤下降76%,作用于H69衍生的肿瘤下降 70%。在相同条件和剂量的情况下,LBH589 作用于NSCLC和Meso衍生的移植瘤,导致SCLC衍生的肿瘤中有两种衰退,伴随着BK-T衍生的平均肿瘤尺寸从实验开始时的296 mm3降低到实验结束时的116 mm3,RG-1衍生的平均肿瘤尺寸从实验开始时的185mm3降低到实验结束时的86 mm3[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
+ 展开
  • Cell lines: MOLT-4细胞和Reh(前体B细胞)
  • Concentrations: 50 nM
  • Incubation Time: 48小时
  • Method: 没有处理的细胞和LBH589处理的细胞[人类急性成淋巴细胞性白血病MOLT-4(T 细胞)和Reh(前体-B细胞)]用膜联蛋白V和碘化丙啶染色,然后加入膜联蛋白V-FITC细胞凋亡检测试剂盒I。通过流式细胞仪测定细胞凋亡和不能存活细胞的百分比。用CyAn ADP Violet细胞计数器收集至少5×104个细胞。根据所有的膜联蛋白V-阳性和膜联蛋白V/PI-阳性细胞细胞计算凋亡百分比,根据所有的膜联蛋白V-阳性和PI-阳性及膜联蛋白V/PI-阳性细胞计算细胞活力丢失百分比。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: 携带10×106个M30细胞或5×106个A549细胞的SCID鼠
  • Formulation: 溶于水的5%葡萄糖
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 349.43
化学式

C21H23N3O2

CAS号 404950-80-7
储存条件 powder
in solvent
别名 NVP-LBH589

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03632317 Withdrawn Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT03515915 Recruiting Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --
NCT02717455 Recruiting Glioma Pediatric Brain Tumor Consortium June 28 2016 Phase 1
NCT02471430 Recruiting HIV Infection Massachusetts General Hospital|Novartis|Genentech Inc. May 2016 Phase 1|Phase 2
NCT02057640 Active not recruiting Multiple Myeloma|Kahler Disease|Plasma-Cell Myeloma|Myelomatosis Case Comprehensive Cancer Center May 22 2014 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound for in vivo mice study?

  • 回答:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Panobinostat (LBH589) | Panobinostat (LBH589)供应商 | 采购Panobinostat (LBH589) | Panobinostat (LBH589)价格 | Panobinostat (LBH589)生产 | 订购Panobinostat (LBH589) | Panobinostat (LBH589)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID